| [1] |
Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis:signaling through lipid rafts[J]. Immunology, 2002, 107(2):176-182.
|
| [2] |
Witzig TE. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy:a new treatment approach for B-cell non-Hodgkin's lymphoma[J]. Drugs Today(Bare), 2004, 40(2):111-119.
|
| [3] |
Emst JA, Li H, Kim HS, et al. Isolation and characterization of the B-cell marker CD20[J]. Biochemistry, 2005, 44(46):15150-15158.
|
| [4] |
Camahan J, Wang P, Kendall R, et al. Epratuzumab,a humanized monoclonal antibody targeting CD22:characterization of in vitro properties[J]. Clin Cancer Res, 2003, 9(10Pt2):3982S-3990S.
|
| [5] |
Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas[J]. Blood, 2003, 101(2):391-398.
|
| [6] |
Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma(DLBCL)[J]. Blood, 2003, 101(11):4279-4284.
|
| [7] |
Shipley DL, Greco FA, Spipel DR, et al. Rituximab with short duration chemotherapy followed by Y90 ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma:update of a minnie pearl cancer research network phase Ⅱ trial[J]. J Clin Oncol, 2005, 23(16S):6577.
|
| [8] |
Bischof-Delaloye A. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL)[J]. Leuk Lymphoma, 2003, 44(Suppl 4):S29-S36.
|
| [9] |
Scheidhauer K, Wolf I, Baumgartl HJ, et al. Biodistribution and kinetics of 131I-labelled anti-CD20 MABIDEC-C2B8(rituximab) in relapsed non-Hodgkin's lymphoma[J]. Eur J Nucl Med Mol Imaging, 2002, 29(10):1276-1282.
|
| [10] |
Turner JH, Martindale AA, Boucek J, et al. 131I-Anti CD20 radioimmunotherapy of relapsed or refraclory non-Hodgkin's lymphoma:a phase Ⅱ clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital[]]. Cancer Biother Radiopharm, 2003, 18(4):513-524.
|
| [11] |
Leahy MF, Seymour JF, Hicks RJ, et al. Multicenter phase Ⅱ clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma[J]. J Clin Oncol, 2006, 24(27):4418-4425.
|
| [12] |
张军一,罗海涛,李爱民,等.131I-美罗华治疗难治性复发性B细胞淋巴瘤9例[J].解放军医学杂志,2003,28(2):190.
|
| [13] |
Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma[J]. Drugs, 2007, 67(3):333-350.
|